{"id":3795,"date":"2022-08-05T19:09:50","date_gmt":"2022-08-05T19:09:50","guid":{"rendered":"https:\/\/www.aohq.ca\/?p=3795"},"modified":"2022-08-05T19:50:07","modified_gmt":"2022-08-05T19:50:07","slug":"hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro","status":"publish","type":"post","link":"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/","title":{"rendered":"H\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae<\/sup>"},"content":{"rendered":"

TORONTO, Ontario, April 28, 2022<\/strong> \u2013 Takeda Canada Inc. is pleased to announce that H\u00e9ma-Qu\u00e9bec has awarded a two-year tender for TAKHZYRO\u00ae (lanadelumab injection) as the sole option for prophylaxis subcutaneous (SC) treatment for type I\/II hereditary angioedema (HAE) patients. The two-year term which begins April 1, 2022, includes the option for H\u00e9ma-Qu\u00e9bec to extend the tender for an additional two years.<\/p>\n

\u201cMy team and I took part in the clinical trials that led to the approval of TAKHZYRO\u00ae, and we are pleased that the medicine is now available for the treatment of patients with hereditary angioedema,\u201d said Dr. Jacques Hebert, Immunology and Allergy Clinic, CHUL. \u201cThe treatment philosophy has evolved over the years. About ten years ago, prophylaxis was used to reduce the morbidity and mortality related to this clinical condition. With modern medicine that is proven to be safe and effective, such as TAKHZYRO\u00ae, prophylaxis aims to help patients lead normal lives without recurrence or attacks.\u201d<\/p>\n

\u201cPatients with hereditary angioedema have long been limited to acute attack treatments. Having access to safe and effective preventive treatment is a major advancement for our patients,\u201d said Dr. R\u00e9mi Gagnon, Head of the Department of Allergy and Immunology, CHU de Qu\u00e9bec. \u201cMany of our Quebec patients have played a pivotal role in this treatment\u2019s development by participating in the research protocols of the Clinique sp\u00e9cialis\u00e9 en allergie de la capitale. Making Lanadelumab available improves patient care by giving them a better quality of life.\u201d<\/p>\n

\u201cPatients with HAE constantly live in fear of their next attack, often disrupting day to day activities such as work, family and social interactions, and significantly impacting their quality of life,\u201d said Charles St. Pierre, President, Hereditary Angioedema Quebec\/Angio-Oedeme Hereditaire du Quebec. \u201cThe HAE community is delighted that TAKHZYRO\u00ae is now available for patients living in Quebec because having access to a treatment option that can prevent attacks would be life-changing for those living with HAE.\u201d<\/p>\n

The awarding of the H\u00e9ma-Qu\u00e9bec tender is the most recent milestone for TAKHZYRO\u00ae since receiving Health Canada authorization for routine prevention of attacks of HAE in adolescents and adults (12 years of age and older) in September 20181. Since then, Health Canada has issued the Notice of Compliance (NOC) for a Prefilled Syringe (300 mg\/ 2 mL) presentation in September 2020, as well as receiving a positive recommendation from CADTH\u2019s Canadian Drug Expert Committee for the routine prevention of HAE attacks in November 2019, and from the Institut national d\u2019excellence en sant\u00e9 et en services sociaux (INESSS) in August 2020.<\/p>\n

\u201cWe\u2019re extremely proud of this agreement with H\u00e9ma-Qu\u00e9bec and what it represents for HAE patients,\u201d said Rute Fernandes, General Manager, Takeda Canada. \u201cThis collaboration is an
\nimportant step to ensure patients with type I and type II HAE have to access TAKHZYRO\u00ae and the improvement of care that is now available to them. This is an example of how our commitment to meeting the needs of patients living with a rare disease has resulted in greater access for patients across the country.\u201d<\/p>\n

About TAKHZYRO\u00ae<\/sup> (lanadelumab injection)<\/h2>\n

TAKHZYRO\u00ae is a fully human monoclonal antibody indicated for routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adults (12 years of age and older)1<\/sup>.<\/p>\n

TAKHZYRO\u00ae is not intended for acute treatment of HAE attacks. Patients and caregivers should continue to be prepared to treat attacks with acute HAE treatments when necessary1<\/sup>.<\/p>\n

It is not known if TAKHZYRO\u00ae is safe and effective in children under 12 years of age1. Consult the current TAKHZYRO\u00ae Canadian product monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use1<\/sup>.<\/p>\n

TAKHZYRO\u00ae is approved in the U.S. (August 2018), E.U. (November 2018), Australia (January 2019) and Switzerland (June 2019) and additional regulatory submissions are ongoing worldwide.<\/p>\n

About Hereditary Angioedema (HAE)<\/h2>\n

HAE is a rare, genetic disorder estimated to affect about 1 in 10,000 to 1 in 50,000 people worldwide23<\/sup>. The condition results in recurring attacks of edema (swelling) in various parts of the body that can be debilitating and painful4253<\/sup>. Laryngeal attacks that obstruct the airways are potentially life-threatening due to the risk of asphyxiation425<\/sup>. Aside from the burden of the disease itself, patients can suffer anxiety, fatigue and depression between attacks6<\/sup>.<\/p>\n

About Takeda Canada Inc.<\/h2>\n

Takeda Canada Inc. is the Canadian organization of Takeda Pharmaceutical Company Limited (TSE: 4502\/NYSE: TAK), a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people\u2019s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit: takeda.com\/en-ca<\/p>\n

Media Contacts:<\/h2>\n

Amanda Jacobs
\namanda.jacobs@takeda.com<\/a>
\n+1 647-798-2231
\n###<\/p>\n

References<\/h2>\n

1 TAKHZYRO Product Monograph; March 2021
\n2 Cicardi M, Bork K, Caballero T, et al, on behalf of HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67(2):147-157.
\n3 Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations, and treatment. Br J Hosp Med. 2006;67(12):654-657.
\n4 Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329-336.
\n5 Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
\n6 Fouche AS, Saunders EFH, Craig T. Depression and anxiety in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2014;112(4):371\u2013375.<\/p>\n","protected":false},"excerpt":{"rendered":"

TORONTO, Ontario, April 28, 2022 \u2013 Takeda Canada Inc. is pleased to announce that H\u00e9ma-Qu\u00e9bec has awarded a two-year tender for TAKHZYRO\u00ae (lanadelumab injection) as the sole option for prophylaxis subcutaneous (SC) treatment for type I\/II hereditary angioedema (HAE) patients. The two-year term which begins April 1, 2022, includes the option for H\u00e9ma-Qu\u00e9bec to extend… Read More<\/a>En savoir plus<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[41],"tags":[],"class_list":["post-3795","post","type-post","status-publish","format-standard","hentry","category-non-classifiee"],"acf":[],"yoast_head":"\nH\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae - Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"H\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae - Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec\" \/>\n<meta property=\"og:description\" content=\"TORONTO, Ontario, April 28, 2022 \u2013 Takeda Canada Inc. is pleased to announce that H\u00e9ma-Qu\u00e9bec has awarded a two-year tender for TAKHZYRO\u00ae (lanadelumab injection) as the sole option for prophylaxis subcutaneous (SC) treatment for type I\/II hereditary angioedema (HAE) patients. The two-year term which begins April 1, 2022, includes the option for H\u00e9ma-Qu\u00e9bec to extend… Read MoreEn savoir plus\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/\" \/>\n<meta property=\"og:site_name\" content=\"Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/aohquebec\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-05T19:09:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-05T19:50:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aohq.366technology.com\/wp-content\/uploads\/2019\/06\/AOH-icon_3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"116\" \/>\n\t<meta property=\"og:image:height\" content=\"63\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@aoh_quebec\" \/>\n<meta name=\"twitter:site\" content=\"@aoh_quebec\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/aohq.366technology.com\/#\/schema\/person\/133469bf357c6878b34b54b40761b8d7\"},\"headline\":\"H\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae\",\"datePublished\":\"2022-08-05T19:09:50+00:00\",\"dateModified\":\"2022-08-05T19:50:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/\"},\"wordCount\":976,\"publisher\":{\"@id\":\"https:\/\/aohq.366technology.com\/#organization\"},\"articleSection\":[\"Non classifi\u00e9(e)\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/\",\"url\":\"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/\",\"name\":\"H\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae - Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec\",\"isPartOf\":{\"@id\":\"https:\/\/aohq.366technology.com\/#website\"},\"datePublished\":\"2022-08-05T19:09:50+00:00\",\"dateModified\":\"2022-08-05T19:50:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/aohq.366technology.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"H\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aohq.366technology.com\/#website\",\"url\":\"https:\/\/aohq.366technology.com\/\",\"name\":\"Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec\",\"description\":\"Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec\",\"publisher\":{\"@id\":\"https:\/\/aohq.366technology.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aohq.366technology.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aohq.366technology.com\/#organization\",\"name\":\"Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec\",\"url\":\"https:\/\/aohq.366technology.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/aohq.366technology.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aohq.366technology.com\/wp-content\/uploads\/2019\/06\/AOH-icon_3.png\",\"contentUrl\":\"https:\/\/aohq.366technology.com\/wp-content\/uploads\/2019\/06\/AOH-icon_3.png\",\"width\":116,\"height\":63,\"caption\":\"Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec\"},\"image\":{\"@id\":\"https:\/\/aohq.366technology.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/aohquebec\/\",\"https:\/\/x.com\/aoh_quebec\",\"https:\/\/www.linkedin.com\/in\/charles-st-pierre-3280aa140\/\",\"https:\/\/www.youtube.com\/channel\/UCErz6mzQo7Qat9YLNFdg-xw\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aohq.366technology.com\/#\/schema\/person\/133469bf357c6878b34b54b40761b8d7\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/aohq.366technology.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/19ca487897e164866b657eb8c82bb8e2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/19ca487897e164866b657eb8c82bb8e2?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/aohq.366technology.com\/en\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"H\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae - Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/","og_locale":"en_US","og_type":"article","og_title":"H\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae - Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec","og_description":"TORONTO, Ontario, April 28, 2022 \u2013 Takeda Canada Inc. is pleased to announce that H\u00e9ma-Qu\u00e9bec has awarded a two-year tender for TAKHZYRO\u00ae (lanadelumab injection) as the sole option for prophylaxis subcutaneous (SC) treatment for type I\/II hereditary angioedema (HAE) patients. The two-year term which begins April 1, 2022, includes the option for H\u00e9ma-Qu\u00e9bec to extend… Read MoreEn savoir plus","og_url":"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/","og_site_name":"Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec","article_publisher":"https:\/\/www.facebook.com\/aohquebec\/","article_published_time":"2022-08-05T19:09:50+00:00","article_modified_time":"2022-08-05T19:50:07+00:00","og_image":[{"width":116,"height":63,"url":"https:\/\/aohq.366technology.com\/wp-content\/uploads\/2019\/06\/AOH-icon_3.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@aoh_quebec","twitter_site":"@aoh_quebec","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/#article","isPartOf":{"@id":"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/"},"author":{"name":"admin","@id":"https:\/\/aohq.366technology.com\/#\/schema\/person\/133469bf357c6878b34b54b40761b8d7"},"headline":"H\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae","datePublished":"2022-08-05T19:09:50+00:00","dateModified":"2022-08-05T19:50:07+00:00","mainEntityOfPage":{"@id":"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/"},"wordCount":976,"publisher":{"@id":"https:\/\/aohq.366technology.com\/#organization"},"articleSection":["Non classifi\u00e9(e)"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/","url":"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/","name":"H\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae - Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec","isPartOf":{"@id":"https:\/\/aohq.366technology.com\/#website"},"datePublished":"2022-08-05T19:09:50+00:00","dateModified":"2022-08-05T19:50:07+00:00","breadcrumb":{"@id":"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/aohq.366technology.com\/en\/non-classifiee\/hema-quebec-awards-takeda-canada-two-year-tender-for-hereditary-angioedema-treatment-takhzyro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/aohq.366technology.com\/en\/"},{"@type":"ListItem","position":2,"name":"H\u00e9ma-Qu\u00e9bec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/aohq.366technology.com\/#website","url":"https:\/\/aohq.366technology.com\/","name":"Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec","description":"Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec","publisher":{"@id":"https:\/\/aohq.366technology.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aohq.366technology.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/aohq.366technology.com\/#organization","name":"Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec","url":"https:\/\/aohq.366technology.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/aohq.366technology.com\/#\/schema\/logo\/image\/","url":"https:\/\/aohq.366technology.com\/wp-content\/uploads\/2019\/06\/AOH-icon_3.png","contentUrl":"https:\/\/aohq.366technology.com\/wp-content\/uploads\/2019\/06\/AOH-icon_3.png","width":116,"height":63,"caption":"Angio-oed\u00e8me H\u00e9r\u00e9ditaire du Qu\u00e9bec"},"image":{"@id":"https:\/\/aohq.366technology.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/aohquebec\/","https:\/\/x.com\/aoh_quebec","https:\/\/www.linkedin.com\/in\/charles-st-pierre-3280aa140\/","https:\/\/www.youtube.com\/channel\/UCErz6mzQo7Qat9YLNFdg-xw"]},{"@type":"Person","@id":"https:\/\/aohq.366technology.com\/#\/schema\/person\/133469bf357c6878b34b54b40761b8d7","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/aohq.366technology.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/19ca487897e164866b657eb8c82bb8e2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/19ca487897e164866b657eb8c82bb8e2?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/aohq.366technology.com\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/aohq.366technology.com\/en\/wp-json\/wp\/v2\/posts\/3795"}],"collection":[{"href":"https:\/\/aohq.366technology.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aohq.366technology.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aohq.366technology.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/aohq.366technology.com\/en\/wp-json\/wp\/v2\/comments?post=3795"}],"version-history":[{"count":0,"href":"https:\/\/aohq.366technology.com\/en\/wp-json\/wp\/v2\/posts\/3795\/revisions"}],"wp:attachment":[{"href":"https:\/\/aohq.366technology.com\/en\/wp-json\/wp\/v2\/media?parent=3795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aohq.366technology.com\/en\/wp-json\/wp\/v2\/categories?post=3795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aohq.366technology.com\/en\/wp-json\/wp\/v2\/tags?post=3795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}